ArticleCancer immunology, immunotherapy : CII2010
Naturally occurring systemic immune responses to HPV antigens do not predict regression of CIN2/3.
Article in Cancer immunology, immunotherapy : CII, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Infiltrating T-cell markers in cervical carcinogenesis: a systematic review and meta-analysis.British journal of cancer · 2021Pooled it
- A pilot study of pNGVL4a-CRT/E7(detox) for the treatment of patients with HPV16+ cervical intraepithelial neoplasia 2/3 (CIN2/3).Gynecologic oncology · 2016Trial
- Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial.Lancet (London, England) · 2015Trial
- Human papillomavirus 16-associated cervical intraepithelial neoplasia in humans excludes CD8 T cells from dysplastic epithelium.Journal of immunology (Baltimore, Md. : 1950) · 2010Trial
- Tuning the fluidity and protein corona of ultrasound-responsive liposomal nanovaccines to program T cell immunity in mice.Nature communications · 2024Article
- The Micro-Immunotherapy Medicine 2LPAPICancers · 2024Article
- Depletion of Human Papilloma Virus E6- and E7-Oncoprotein-Specific T-Cell Responses in Women Living With HIV.Frontiers in immunology · 2021Article
- T Cell Receptor Repertoires AcquiredFrontiers in immunology · 2021Article
- The association between HIV infection and cervical cancer presentation and survival in Uganda.Gynecologic oncology reports · 2020Review
- Performance of a DNA methylation marker panel using liquid-based cervical scrapes to detect cervical cancer and its precancerous stages.BMC cancer · 2018Article
- Current therapeutic vaccination and immunotherapy strategies for HPV-related diseases.Human vaccines & immunotherapeutics · 2016Review
- CIN III lesions and regression: retrospective analysis of 635 cases.BMC infectious diseases · 2015Article
- Immunoprevention of human papillomavirus-associated malignancies.Cancer prevention research (Philadelphia, Pa.) · 2015Review
- Toll-like receptor agonist imiquimod facilitates antigen-specific CD8+ T-cell accumulation in the genital tract leading to tumor control through IFNγ.Clinical cancer research : an official journal of the American Association for Cancer Research · 2014Article
- Clearance of persistent HPV infection and cervical lesion by therapeutic DNA vaccine in CIN3 patients.Nature communications · 2014Article
- Intramuscular therapeutic vaccination targeting HPV16 induces T cell responses that localize in mucosal lesions.Science translational medicine · 2014Article
- CD4+ T-cell response against human papillomavirus type 16 E6 protein is associated with a favorable clinical trend.Cancer immunology, immunotherapy : CII · 2012Article
- Therapeutic Human Papillomavirus (HPV) Vaccines: A Novel Approach.The open virology journal · 2012Article
- Direct identification of an HPV-16 tumor antigen from cervical cancer biopsy specimens.Frontiers in immunology · 2011Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Essentially all squamous cervical cancers and their precursor lesions, high grade cervical intraepithelial neoplasia (CIN2/3), are caused by persistent human papillomavirus (HPV) infection. However, not all CIN2/3 lesions progress to cancer. In a brief, observational study window monitoring subjects with CIN2/3 from protocol entry (biopsy diagnosis) to definitive therapy (cervical conization) at week 15, in a cohort of 50 subjects, we found that 26% of CIN2/3 lesions associated with HPV16, the genotype most commonly associated with disease, underwent complete histologic regression. Nonetheless, HPV16-specific T cell responses measured in peripheral blood obtained at the time of study entry and at the time of conization were marginally detectable directly ex vivo, and did not correlate with lesion regression. This finding suggests that, in the setting of natural infection, immune responses which are involved in elimination of cervical dysplastic epithelium are not represented to any great extent in the systemic circulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.